TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02580526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: V-E mask ventilation for one minute
Description: V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: V-E mask ventilation for one minute
Description: V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: C-E mask ventilation for one minute
Description: Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: C-E mask ventilation for one minute
Description: Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique.
Study: NCT01318564

Intervention type: DRUG
Intervention: Metformin
Description: 500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).

Intervention type: DRUG
Intervention: Metformin
Description: 500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
Study: NCT02604589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydromorphone hydrochloride
Description: Patient-controlled narcotic analgesia pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydromorphone hydrochloride
Description: Patient-controlled narcotic analgesia pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydromorphone hydrochloride
Description: Patient-controlled narcotic analgesia pump

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion catheter placement
Description: Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion catheter placement
Description: Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine 0.25%
Description: Low Dose analgesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivicaine 0.5%
Description: High dose analgesia
Study: NCT03526523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: 8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
Study: NCT01351740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: switch to unboosted atazanavir 400 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/ritonavir
Description: Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
Study: NCT04120389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)
Description: wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
Study: NCT04388332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structural allograft
Description: Subjects that have received ACDF structural allograft with plates with autograft and/or allograft comprised of cancellous and/or corticocancellous bone chips

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tritanium C
Description: Subjects will receive the Tritanium C anterior cervical cage which is intended to be used with autogenous or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft
Study: NCT04111497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Given PO
Study: NCT04054167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy
Description: Undergo ultra low dose radiation
Study: NCT00420680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
Study: NCT03736265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
Study: NCT03020914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual Distraction
Description: watching a movie using video glasses and headphones
Study: NCT03284957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT03284957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Pharmaceutical form: tablet
Study: NCT02661828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two-Week Antidepressant Taper Regimen
Description: Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
Study: NCT04607772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Dose: 12 mg/kg
Study: NCT02661828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-Week Antidepressant Taper Regimen
Description: Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
Study: NCT04607772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Dose: 200, 400, 600, 800 mg
Study: NCT01936259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Stem
Description: The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano
Description: The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
Study: NCT04184076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) with dietary counseling
Description: 1. Subjects will be instructed to administer time-restricted feeding.~2. Subjects have to compete a 3-d food record, including 2 regular day and 1 holiday. At baseline, a dietitian will provide 15 min of instruction to each participant on how to complete the food records. Subjects will be asked to measure the volume of foods consumed with household measures. The timing of food intake will be also recorded. Food records will be collected each week during the experiment and will be reviewed by the dietitian for accuracy and completeness. A database for food content will be used to calculate the total daily intake of energy, fat, protein, carbohydrate, cholesterol, and fiber. All subjects will be asked to maintain their level of physical activity throughout the entire trial.~3. Blood withdraw will be performed prior to the first consumption of food and analyze some biochemistry data.
Study: NCT01961869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast release BRB confection
Description: Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast release BRB confection
Description: Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermed release BRB confection
Description: Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermed release BRB confection
Description: Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolong release BRB confection
Description: Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolong release BRB confection
Description: Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
Study: NCT03513029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VytronUS Ablation System
Description: Catheter Ablation for Paroxysmal Atrial Fibrillation
Study: NCT04678414

Intervention type: BEHAVIORAL
Intervention: Healthcare Activity
Description: Attend focus group

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT02046434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Phenylbutyrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Phenylbutyrate
Study: NCT04670016

Intervention type: OTHER
Intervention: This study does not include an intervention.
Description: This study does not include an intervention.

Intervention type: OTHER
Intervention: This study does not include an intervention.
Description: This study does not include an intervention.
Study: NCT00763542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for SUD
Description: CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for SUD
Description: CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured writing therapy for PTSD
Description: Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
Study: NCT04607772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose: 1000 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose: 100 mg/m\^2
Study: NCT01956175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical pharyngeal stimulation
Description: Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
Study: NCT01251796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197 and Erlotinib
Description: Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
Study: NCT02826889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Intelivue MP70 monitor
Description: Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleth Variability Index (PVI)
Description: PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
Study: NCT03511560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet
Description: Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
Study: NCT01542866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Management Tool (HMT)
Description: Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
Study: NCT04313192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse rate of 2 Hz
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse rate of 10 Hz
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse rate of 150 Hz
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
Study: NCT03251924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986226
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986226
Description: specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986226
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Vaccine
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Vaccine
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Vaccine
Description: specified dose on specified days
Study: NCT01544244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GSC physical therapy
Description: Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
Study: NCT03169153

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon C contact lenses
Description: Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon C contact lenses
Description: Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
Study: NCT02327208

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Study: NCT01301248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiation plus Cetuximab
Description: Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
Study: NCT00529165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection-meal-interval
Description: The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection-meal-interval
Description: The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~1. Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~2. Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks.